Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jasplakinolide is a naturally occurring cyclic depsipeptide originally isolated from the marine sponge *Jaspis johnstoni*. It is a potent inducer of actin polymerization and a stabilizer of F-actin filaments. By binding to F-actin with high affinity, it competes with phalloidin and promotes the nucleation of actin monomers into filaments, effectively lowering the critical concentration for polymerization. In therapeutic research, it is being explored for its ability to stabilize the endothelial cytoskeleton and enhance the microvascular barrier, particularly in the context of Acute Lung Injury (ALI). It also exhibits antifungal and anti-tumor properties, though its high toxicity has historically limited its clinical use. Recent investigations have focused on liposome-mediated delivery to target lung microvessels specifically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jasplakinolide.